J.P. Marvel Investment Advisors LLC Grows Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)

J.P. Marvel Investment Advisors LLC raised its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 34.8% during the 1st quarter, Holdings Channel reports. The firm owned 29,060 shares of the medical research company’s stock after buying an additional 7,500 shares during the period. J.P. Marvel Investment Advisors LLC’s holdings in Charles River Laboratories Intl. were worth $4,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the business. Fort L.P. acquired a new position in shares of Charles River Laboratories Intl. in the fourth quarter valued at about $27,000. Tompkins Financial Corp grew its stake in shares of Charles River Laboratories Intl. by 63.1% in the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 77 shares in the last quarter. Riverview Trust Co acquired a new position in shares of Charles River Laboratories Intl. in the fourth quarter valued at about $30,000. Sageworth Trust Co acquired a new position in shares of Charles River Laboratories Intl. in the first quarter valued at about $37,000. Finally, Kwmg LLC grew its stake in shares of Charles River Laboratories Intl. by 32.4% in the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.38% of the company’s stock.

Several equities analysts recently commented on CRL shares. Barclays upped their price target on shares of Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, March 18th. KeyCorp upped their price target on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research note on Monday, March 11th. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Wolfe Research started coverage on shares of Charles River Laboratories Intl. in a research note on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Finally, Evercore ISI restated an “outperform” rating and issued a $160.00 price target on shares of Charles River Laboratories Intl. in a research note on Tuesday, April 30th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $146.27.

CRL opened at $129.88 on Monday. Charles River Laboratories Intl. Inc has a twelve month low of $103.00 and a twelve month high of $149.07. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39. The stock has a market cap of $6.31 billion, a P/E ratio of 21.54, a PEG ratio of 1.66 and a beta of 1.05.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.02. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The business had revenue of $604.57 million during the quarter, compared to analysts’ expectations of $587.65 million. During the same quarter in the prior year, the business posted $1.29 earnings per share. Charles River Laboratories Intl.’s revenue was up 22.4% compared to the same quarter last year. As a group, analysts anticipate that Charles River Laboratories Intl. Inc will post 6.48 EPS for the current fiscal year.

In other news, Director George Massaro sold 1,002 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $131.38, for a total value of $131,642.76. Following the completion of the transaction, the director now owns 11,204 shares of the company’s stock, valued at $1,471,981.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William D. Barbo sold 4,905 shares of the stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total transaction of $613,909.80. Following the completion of the transaction, the insider now directly owns 25,859 shares of the company’s stock, valued at approximately $3,236,512.44. The disclosure for this sale can be found here. Insiders have sold 9,047 shares of company stock valued at $1,168,322 in the last ninety days. 1.80% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “J.P. Marvel Investment Advisors LLC Grows Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://theenterpriseleader.com/2019/06/17/j-p-marvel-investment-advisors-llc-grows-holdings-in-charles-river-laboratories-intl-inc-nysecrl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: How Do Investors Open a Backdoor Roth IRA?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.